- Charles River Laboratories will close its cell therapy contract development and manufacturing site in Hanover, Maryland, eliminating 20 positions, according to a WARN filing.
- Client work from the site is expected to transition to other locations by the second quarter of 2026.
Charles River Laboratories said it will close its cell therapy contract development and manufacturing site in Hanover, Maryland, resulting in the elimination of 20 positions. The closure was disclosed in a state Worker Adjustment and Retraining Notification filing.
The decision forms part of an ongoing restructuring at the Boston-based contract research organization. The company has been reducing headcount and exiting selected operations following a strategic review. Charles River said it determined the Hanover facility was not a strategic fit.
Client programs currently supported at the site will be transitioned to other Charles River locations by the second quarter of 2026. The company said it will provide transition support to affected employees and may offer some opportunities for redeployment into other roles.
The company has not stated whether further reductions are planned within its cell therapy CDMO or broader contract manufacturing operations. The Hanover closure follows other recent workforce reductions, including the layoff of about 70 employees at Charles River’s Wilmington, Massachusetts, facility in November after research model production was shifted to other sites.
